Skip to main content

Table 4 p53 status and prognosis of colorectal cancer: past literature date

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Reference n Histology treatment Methods for determing p53 Ab IHC Sequencing Frequency alterd p53 pathway (%) Prognostic value
Overall survial Survival Response
LAN YT [10] 258 ACC surgery - + - 37.6(IHC) univariate NA NA
Triantafyllou K [11] 55 Adenoma Polypectomy - + - 41.8DtHCD NA murtivariate NA
Wang Q [12] 40 ACC surgery - + - 65 OHCD univariate NA NA
Hu J [13] 120 ACC biopsy and surgery - + - 57 OHCD univariate NA NA
Grewal H [14] 66 ACC surgery - + - 51.5(IHC) NS NA NA
Bouzourenne H [15] 122 ACC surgery - + + 47(IHC) univariate NA NA
32(S) murtivariate
Samowitz WS [16] 1464 ACC biopsy and surgery - - + 45.4DSD univariate NA NA
Chang SC [17] 167 ACC surgery + - + 28.1(Ab) univariate NA NA
56.3(S) murtivariate
Angelopoulou K [18] 229 ACC biopsy and surgery + - - 23(Ab) NS NS NA
Kressner U [19] 184 ACC surgery + - - 32(Ab) univariate NA NA
Suppiah A [20] 28 ACC surgery + - - 21,7(Ab) NS NS NA
Kreessner U [21] 294 ACC biopsy + - - 55DAbD NS NA NA
  1. Ab antibody; IHC immunohistochemistry; S sequencing; ACC advanced colorectal cancer; NA not available; NS not significant